vimarsana.com

Latest Breaking News On - Receptor antagonists - Page 1 : vimarsana.com

Pharvaris Announces Extraordinary Meeting of Shareholders

ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the extraordinary general meeting of shareholders will take place on Wednesday, March 6, 2024, at 12:00 CST (6:00 a.m. EST). All relevant documents and information relating to the extraordinary general meeting, including the notice and agenda for the extraordinary

Pulmonary Arterial Hypertension Treatment Industry Poised to Surpass US$ 6 6 Billion by 2028-FMI Rep

The pulmonary arterial hypertension (PAH) treatment industry stands as a beacon of hope for individuals grappling with this rare but serious condition that affects the heart and lungs. PAH involves abnormally high blood pressure in the arteries that connect the heart and lungs, leading to reduced blood flow and stra.

Safety vs Price in the Generic Drug Market: Metformin

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.